A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

Inclusion Criteria:

• Diagnosed with rheumatoid arthritis (RA) based on American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for at least 3 monthsprior to screening

• Demonstrated an inadequate response to, or loss of response or intolerance to atleast 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) (Hydroxychloroquine, methotrexate [MTX], leflunomide, or sulfasalazine) or 1biologic disease-modifying antirheumatic drug (bDMARD)/targeted syntheticdisease-modifying antirheumatic drug (tsDMARD) treatment

• Must be on stable dose of one of the following permitted therapies for ≥ 4 weeksprior to screening and during the study: methotrexate between 7.5 mg to 25 mg/week,hydroxychloroquine up to 400 mg/day, leflunomide up to 20 mg/day, or sulfasalazinebetween 1000 mg/day to 3000 mg/day

Exclusion Criteria:

• Class IV RA based on American College of Rheumatology revised criteria forclassification of functional status in rheumatoid arthritis

• Patients with a history of cancer in the last 5 years before the Screening Visit,with the exception of adequately treated basal cell or squamous cell carcinoma ofthe skin

• Have failed more than 2 b/tsDMARDs (eg, excluded if have failed 2 bDMARDs and 1tsDMARD)